Treatment of refractory T-cell malignancies using gemcitabine.
We have treated 10 patients with relapsed or refractory T-cell malignancies using gemcitabine. The drug was administered intravenously over 30 min at a dose of 1200 mg/m2 on d 1, 8 and 15 of each 28-d cycle. The mean age of the patients was 62 years and the mean number of administered cycles was three. Of the 10 patients, two achieved a complete response and four a partial response, for an overall response rate of 60% (95% confidence interval 20--35%). The toxicity of chemotherapy was mild and manageable in all patients. These encouraging results warrant further investigation of gemcitabine either as a single agent or in combination regimens as early salvage treatment for patients with refractory T-cell haematological neoplasms.
Sallah
S
S
Department of Medicine, Division of Hematology/Oncology, University of Tennessee Health Science Center, Memphis, TN 38103, USA. ssallah@utmem.edu
Wan
J Y
JY
Nguyen
N P
NP
D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage* / Q000031:analogs & derivatives; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D015463:Leukemia, Prolymphocytic / Q000188:drug therapy*; D016399:Lymphoma, T-Cell / Q000188:drug therapy*; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy; D016411:Lymphoma, T-Cell, Peripheral / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D016879:Salvage Therapy; D016896:Treatment Outcome; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D000093542:Gemcitabine